Original article
Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature

https://doi.org/10.1016/S0748-7983(97)80140-0Get rights and content

The clinico-pathological features of 53 Chinese patients (27 males; 26 females) with pancreatic endocrine tumours were studied. The age range was from 14 to 78 years old (mean: 48 years) with the modal peak in the sixth decade for both sexes. Pancreatic endocrine tumours accounted for 14% of the primary pancreatic tumours operated on in Queen Mary Hospital. The autopsy incidence was 0.11%. Seventy-two per cent (38 cases) of the tumours were clinically functioning, comprising 33 insulinomas, three gastrinomas and two glucagonomas. A rare case of malignant gastrinoma associated with Cushing's syndrome was also documented. The functional tumours were seen in the younger patients. The calculated annual incidence of clinically significant tumours was approximately 0.2 per 100,000 population. There was no correlation between the site, functional status and histological patterns of the tumours. Seventy-two per cent of the tumours showed a trabecular pattern. Calcification was present in 5.7% (three cases); two such cases being gastrinomas. Amyloid was found in 25% of tumours, chiefly (92%) in the insulinomas. The main difficulty encountered in diagnosis was distinguishing between solid and cystic tumours of the pancreas. The incidence of malignancy was 15% and the histological features were poor predicative indicators of malignant potential. The metastatic pancreatic endocrine tumours were often detected in the liver and lymph nodes. Immunohistochemical stains showed evidence of multi-hormone production in 18% of cases and all tumours showed a positive reaction to at least one of the six markers, namely, neuron-specific enolase (NSE), chromogrannin (CG), synaptophysin (SYN), insulin (INS), glucagon (GLU) or somatostatin (SOM). The three panendocrine markers (NSE, SYN, CG) were satisfactory for initial screening of the endocrine nature of the tumours if used in combination, as 92% of tumours were positive for at least one of these three markers.

References (46)

  • WatMS et al.

    Clinico-pathological correlation of glucagon-positive pancreatic tumours: a presentation of five cases

    Eur J Surg Oncol

    (1995)
  • LiuTH et al.

    Insulinoma: an immunohistochemical and morphologic analysis of 95 cases

    Cancer

    (1985)
  • ChangHY et al.

    Insulinoma-clinical experience in ten cases

    Chang Gung Med J

    (1994)
  • HsuS et al.

    A comparative study of peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies

    Am J Clin Pathol

    (1981)
  • CreutzfeldtW

    Endocrine tumors of the pancreas: clinical, chemical and morphological findings

    Mongr Pathol

    (1980)
  • KimuraW et al.

    Clinical pathology of endocrine tumors of the pancreas: analysis of autopsy cases

    Dig Dis Sci

    (1991)
  • ErikssonB et al.

    Neuroendocrine pancreatic tumors: clinical findings in a prospective study of 84 patients

    Acta Oncol

    (1989)
  • MukaiK et al.

    Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method

    Am J Surg Pathol

    (1982)
  • KentRB et al.

    Nonfunctioning islet cell tumors

    Ann Surg

    (1981)
  • EckhauserFE et al.

    Non-functioning malignant neurodendocrine tumors of the pancreas

    Surgery

    (1986)
  • BordiC et al.

    Comparative study of seven neuroendocrine markers in pancreatic endocrine tumours

    Virch Archiv

    (1988)
  • YamaguchiK et al.

    Endocrine neoplasms of the pancreas: a clinicopathologic study of 24 cases and immunohistochemical remarks

    Jpn J Surg

    (1992)
  • GramaD et al.

    Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes

    World J Surg

    (1992)
  • Cited by (107)

    • Diabetes mellitus associated with pancreatic somatostatin tumor: A case report

      2016, Journal of Clinical and Translational Endocrinology: Case Reports
      Citation Excerpt :

      Pancreatic neuroendocrine tumor (PNET) is an uncommon neoplasm with an incidence of 2.2/1,000,000 [1]. PNET accounts for 1–2% of all pancreatic tumors [2–4], including nonfunctional tumors and functional tumors such as insulinoma, gastrinoma, glucagonoma, vasoactive intestinal polypeptidoma (VIPoma) and somatostatinoma [5]. Most pancreatic tumors are nonfunctional, and the most common functional tumor is insulinoma [6].

    • Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: A meta-analysis

      2015, Gastrointestinal Endoscopy
      Citation Excerpt :

      IBEUS is greater for functioning compared with nonfunctioning PNETs. Functioning PNETs usually are diagnosed at an earlier stage and smaller size because their hormone secretions give rise to symptoms.29,30 Nonfunctioning PNETs, on the other hand, remain clinically silent until they are either detected incidentally or cause symptoms—mainly by compressing adjacent organs.29,30

    • Epidemiology and Classification of Neuroendocrine Tumors of the Pancreas

      2023, The Pancreas: an Integrated Textbook of Basic Science, Medicine, and Surgery, Fourth Edition
    View all citing articles on Scopus
    View full text